These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29062399)

  • 1. Self-reported Hypoglycaemia in Patients treated with Insulin: A Large Slovenian Retrospectively-prospective Study.
    Pongrac Barlovič D; Zavratnik A; Skvarča A; Janša K; Vukelič B; Tomažič M; Ravnik Oblak M
    Zdr Varst; 2017 Oct; 56(4):244-250. PubMed ID: 29062399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Self-reported Hypoglycaemic Events in 2 430 Patients with Insulin-treated Diabetes in the German Sub-population of the HAT Study.
    Kern W; Holstein A; Moenninghoff C; Kienhöfer J; Riedl M; Kulzer B
    Exp Clin Endocrinol Diabetes; 2017 Oct; 125(9):592-597. PubMed ID: 28750429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Self-reported non-severe hypoglycaemic events in Europe.
    Östenson CG; Geelhoed-Duijvestijn P; Lahtela J; Weitgasser R; Markert Jensen M; Pedersen-Bjergaard U
    Diabet Med; 2014 Jan; 31(1):92-101. PubMed ID: 23796113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study.
    Khunti K; Alsifri S; Aronson R; Cigrovski Berković M; Enters-Weijnen C; Forsén T; Galstyan G; Geelhoed-Duijvestijn P; Goldfracht M; Gydesen H; Kapur R; Lalic N; Ludvik B; Moberg E; Pedersen-Bjergaard U; Ramachandran A;
    Diabetes Obes Metab; 2016 Sep; 18(9):907-15. PubMed ID: 27161418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoglycaemia among Insulin-Treated Patients with Diabetes: Southeast Asia Cohort of IO HAT Study.
    Pathan F; Goh SY; Rudijanto A; Gadekar A; Jain A; Nicodemus N
    J ASEAN Fed Endocr Soc; 2018; 33(1):28-36. PubMed ID: 33442108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoglycaemia Among Insulin-Treated Patients with Diabetes: Evaluation of the United Arab Emirates cohort of the International Operations-Hypoglycaemia Assessment Tool study.
    Abusnana S; Beshyah SA; Al-Mutawa N; Tahhan R; Jallo M; Arora R; Aly H; Singhal S
    Sultan Qaboos Univ Med J; 2018 Nov; 18(4):e447-e454. PubMed ID: 30988962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study.
    Donnelly LA; Morris AD; Frier BM; Ellis JD; Donnan PT; Durrant R; Band MM; Reekie G; Leese GP;
    Diabet Med; 2005 Jun; 22(6):749-55. PubMed ID: 15910627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world patient-reported rates of non-severe hypoglycaemic events in Germany.
    Kulzer B; Seitz L; Kern W
    Exp Clin Endocrinol Diabetes; 2014 Mar; 122(3):167-72. PubMed ID: 24643694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe hypoglycaemia in patients with type 1 diabetes and impaired awareness of hypoglycaemia: a comparative study of insulin lispro and regular human insulin.
    Ferguson SC; Strachan MW; Janes JM; Frier BM
    Diabetes Metab Res Rev; 2001; 17(4):285-91. PubMed ID: 11544612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The influence of long-term therapy with the insulin pump (CSII) in patients with type 1 diabetes mellitus on metabolic compensation and on the incidence of hypoglycaemia. Comparison with intensified conventional insulin therapy (MDI)].
    Olsovský J; Beránek M
    Vnitr Lek; 2007 Jun; 53(6):637-45. PubMed ID: 17702123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial.
    Heinemann L; Freckmann G; Ehrmann D; Faber-Heinemann G; Guerra S; Waldenmaier D; Hermanns N
    Lancet; 2018 Apr; 391(10128):1367-1377. PubMed ID: 29459019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching to Degludec is Associated with Reduced Hypoglycaemia, Irrespective of Definition Used or Patient Characteristics: Secondary Analysis of the ReFLeCT Prospective, Observational Study.
    de Valk HW; Feher M; Hansen TK; Jendle J; Koefoed MM; Rizi EP; Zimmermann E; Fadini GP
    Diabetes Ther; 2020 Sep; 11(9):2159-2167. PubMed ID: 32666165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported frequency, awareness and patient-physician communication of hypoglycaemia in Belgium.
    Peene B; D'Hooge D; Vandebrouck T; Mathieu C
    Acta Clin Belg; 2014 Dec; 69(6):439-45. PubMed ID: 25212241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of perceived stress, concern about hypoglycaemia and level of knowledge of management of the disease on glycaemic control in type 1 diabetes mellitus.
    Grau-Del Valle C; Marco-Expósito JF; Bosch-Sierra N; Zaragoza-Villena B; Solá E; Montoya-Castilla I; Morillas C; Bañuls C
    J Clin Nurs; 2023 Jan; 32(1-2):264-272. PubMed ID: 35224806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency and predictors of confirmed hypoglycaemia in type 1 and insulin-treated type 2 diabetes mellitus patients in a real-life setting: results from the DIALOG study.
    Cariou B; Fontaine P; Eschwege E; Lièvre M; Gouet D; Huet D; Madani S; Lavigne S; Charbonnel B
    Diabetes Metab; 2015 Apr; 41(2):116-25. PubMed ID: 25465273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries.
    Khunti K; Caputo S; Damci T; Dzida GJ; Ji Q; Kaiser M; Karnieli E; Liebl A; Ligthelm RJ; Nazeri A; Orozco-Beltran D; Pan C; Ross SA; Svendsen AL; Vora J; Yale JF; Meneghini LF;
    Diabetes Obes Metab; 2012 Dec; 14(12):1129-36. PubMed ID: 22830956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 U/mL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study.
    Wolnik B; Wiza D; Szczepanik T; Syta A; Klupa T
    J Diabetes Res; 2020; 2020():8751348. PubMed ID: 32337298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial.
    Philis-Tsimikas A; Klonoff DC; Khunti K; Bajaj HS; Leiter LA; Hansen MV; Troelsen LN; Ladelund S; Heller S; Pieber TR;
    Diabetologia; 2020 Apr; 63(4):698-710. PubMed ID: 31984443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.